Complications of chemotherapy for prostate cancer

Seminars in Urologic Oncology

Volumn 19, Issue 3, 2001, Pages 222-230

  Beer, T M ^a   Bubalo, J S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adverse effects; Chemotherapy; Complications; Prostate cancer; Toxicity

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BETASEPT; CARBOPLATIN; CHLORHEXIDINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; DOPAMINE; DOXORUBICIN; DRUG VEHICLE; ESTRAMUSTINE; ETOPOSIDE; GRANISETRON; KETOCONAZOLE; LOPERAMIDE; LORAZEPAM; METOCLOPRAMIDE; MITOXANTRONE; NAVELBINE; ONDANSETRON; PACLITAXEL; PREDNISONE; PROCHLORPERAZINE MALEATE; SEDATIVE AGENT; SEROTONIN; STEROID; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE SULFATE;

ALOPECIA; ANOREXIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG SPECIFICITY; DRUG TOLERABILITY; GROWTH INHIBITION; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR;

ADENOCARCINOMA; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; GASTROINTESTINAL DISEASES; HUMANS; MALE; MITOXANTRONE; NERVOUS SYSTEM DISEASES; PACLITAXEL; PREDNISONE; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 0034868459     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer
2. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy
3. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer
4. Chemotherapy with Mitoxantrone plus Prednisone or Prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
5. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer
6. Prevention and treatment of oral mucositis following cancer chemotherapy
7. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines
8. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery
9. Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy
10. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases
11. Local and systemic radiation for palliation of metastatic disease
12. Geriatric clinical pharmacologist and medical oncologist: A new partnership?
13. Clinical pharmacology of paclitaxel in relation to patient age: CALGB 9762
14. Acute myelogenous leukemia and aging: Clinical interactions
15. Non-Hodgkin's lymphoma in the elderly: A guide to drug treatment
16. Chemotherapy in the elderly
17. Pharmacology of cancer chemotherapy in the older person
18. Cancer chemotherapy in the older patient: What the medical oncologist needs to know
19. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
20. Phase 11 trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
21. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
22. Phase I/II studies of docetaxel (taxotere) combined with estramustine in men with hormone-refractory prostate cancer
23. A phase II study of docetaxel (taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780
24. Preliminary evaluation of docetaxel plus 1-day estramustine in the treatment of prostate cancer
25. Docetaxel (taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
26. A phase II trial of docetaxel (taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2
27. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer
28. Weekly docetaxel for hormone-refractory prostate cancer
29. Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix
30. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate
31. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer
32. Oral estramustine and oral etoposide for hormone-refractory prostate cancer
33. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial
34. Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo
35. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
36. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
37. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer
38. Defining the emetogenicity of cancer chemotherapy regimens: Relevance to clinical practice
39. What primary care physicians should know about the toxicity of cancer chemotherapy
40. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity
41. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
42. Practical treatment guide for dose individualisation in cancer chemotherapy
43. Adaptive control methods for the dose individualisation of anticancer agents